Value-based healthcare in the UK: A system of trial and error

This Economist Intelligence Unit (EIU) report, commissioned by Gilead Sciences, explores important questions about the UK healthcare system.

Martin Koehring
Martin Koehring
Senior Manager for Sustainability, Climate Change and Natural Resources & Head of the World Ocean Initiative, Economist Enterprise

29 Feb 2016

Value-based healthcare in the UK: A system of trial and error

Value-based healthcare looks at health outcomes of treatment relative to cost. In this particular report The EIU examines the structure of UK healthcare delivery, the unique model used by its health technology assessment (HTA) agencies, and its history of experimentation in value-based pricing.

Download Full Report

Further reading:


Value-based healthcare in Portugal: Necessity is the mother of invention
Supported by Gilead and Kite

Value-based healthcare in Portugal: Necessity is the mother of invention

This paper examines how the recent economic crisis has shaped health technology assessment; the role of the hospital sector; and promising initiatives in integrated care, family health units and a new process for the re-evaluation of health technologies.

Value-based healthcare in France: A slow adoption of cost-effectiveness criteria
Supported by Gilead and Kite

Value-based healthcare in France: A slow adoption of cost-effectiveness criteria

This new Economist Intelligence Unit (EIU) report, commissioned by Gilead Sciences, explores important questions about the French healthcare system. How is healthcare innovation assessed in France? To what extent is value for money influencing price neg

Value-based healthcare in Spain: Regional experimentation in a shared governance setting
Supported by Gilead and Kite

Value-based healthcare in Spain: Regional experimentation in a shared governance setting

Value-based healthcare in Spain is an Economist Intelligence Unit (EIU) report, commissioned by Gilead Sciences. It looks at health outcomes of treatment relative to cost and at the structure of Spanish healthcare delivery.

Value-based Healthcare in Germany: From free price-setting to a regulated market
Supported by Gilead and Kite

Value-based Healthcare in Germany: From free price-setting to a regulated market

This report looks at the evolution of health technology assessment and pharmaceutical pricing reform in Germany and examines the new focus on providers and health outcomes.